与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 425 - Prospectuses and communications, business combinations Filed: 2018-06-07 AccNo: 0001104659-18-038671 Size: 49 KB 网页链接
$井寺制药(IDRA)$ DEFM14A - Definitive proxy statement relating to merger or acquisition Filed: 2018-05-30 AccNo: 0001047469-18-004164 Size: 3 MB 网页链接
$井寺制药(IDRA)$ DEFM14A - Definitive proxy statement relating to merger or acquisition Filed: 2018-05-30 AccNo: 0001047469-18-004164 Size: 3 MB 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2018-05-24 AccNo: 0001104659-18-035587 Size: 24 KBItem 1.01: Entry into a Material Definitive Agreement 网页链接
$井寺制药(IDRA)$ DEF 14A - Other definitive proxy statements Filed: 2018-05-22 AccNo: 0001047469-18-003949 Size: 1 MB 网页链接
$井寺制药(IDRA)$ PRE 14A - Other preliminary proxy statements Filed: 2018-05-10 AccNo: 0001047469-18-003677 Size: 1 MB 网页链接
$井寺制药(IDRA)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-05-09 AccNo: 0001558370-18-004402 Size: 5 MB 网页链接
$井寺制药(IDRA)$ 425 - Prospectuses and communications, business combinations Filed: 2018-04-10 AccNo: 0001104659-18-023165 Size: 38 KB 网页链接
$井寺制药(IDRA)$ 425 - Prospectuses and communications, business combinations Filed: 2018-04-02 AccNo: 0001104659-18-021843 Size: 55 KB 网页链接
$井寺制药(IDRA)$ 425 - Prospectuses and communications, business combinations Filed: 2018-04-02 AccNo: 0001104659-18-021700 Size: 28 KB 网页链接